Cargando…
Randomized Phase II study of the safety, efficacy and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR)
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645503/ http://dx.doi.org/10.1186/2051-1426-3-S2-P155 |
| _version_ | 1782400827321745408 |
|---|---|
| author | Le, Dung T Crocenzi, Todd S Urum, Jennifer N Lutz, Eric R Laheru, Daniel A Sugar, Elizabeth A Vonderheide, Robert H Fisher, George A Ko, Andrew H Murphy, Aimee L McDougall, Katherine Ferber, Sandy Brockstedt, Dirk G Jaffee, Elizabeth M |
| author_facet | Le, Dung T Crocenzi, Todd S Urum, Jennifer N Lutz, Eric R Laheru, Daniel A Sugar, Elizabeth A Vonderheide, Robert H Fisher, George A Ko, Andrew H Murphy, Aimee L McDougall, Katherine Ferber, Sandy Brockstedt, Dirk G Jaffee, Elizabeth M |
| author_sort | Le, Dung T |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4645503 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-46455032015-11-20 Randomized Phase II study of the safety, efficacy and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR) Le, Dung T Crocenzi, Todd S Urum, Jennifer N Lutz, Eric R Laheru, Daniel A Sugar, Elizabeth A Vonderheide, Robert H Fisher, George A Ko, Andrew H Murphy, Aimee L McDougall, Katherine Ferber, Sandy Brockstedt, Dirk G Jaffee, Elizabeth M J Immunother Cancer Poster Presentation BioMed Central 2015-11-04 /pmc/articles/PMC4645503/ http://dx.doi.org/10.1186/2051-1426-3-S2-P155 Text en Copyright © 2015 Le et al. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Le, Dung T Crocenzi, Todd S Urum, Jennifer N Lutz, Eric R Laheru, Daniel A Sugar, Elizabeth A Vonderheide, Robert H Fisher, George A Ko, Andrew H Murphy, Aimee L McDougall, Katherine Ferber, Sandy Brockstedt, Dirk G Jaffee, Elizabeth M Randomized Phase II study of the safety, efficacy and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR) |
| title | Randomized Phase II study of the safety, efficacy and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR) |
| title_full | Randomized Phase II study of the safety, efficacy and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR) |
| title_fullStr | Randomized Phase II study of the safety, efficacy and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR) |
| title_full_unstemmed | Randomized Phase II study of the safety, efficacy and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR) |
| title_short | Randomized Phase II study of the safety, efficacy and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR) |
| title_sort | randomized phase ii study of the safety, efficacy and immune response of gvax pancreas (with cyclophosphamide) and crs-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (stellar) |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645503/ http://dx.doi.org/10.1186/2051-1426-3-S2-P155 |
| work_keys_str_mv | AT ledungt randomizedphaseiistudyofthesafetyefficacyandimmuneresponseofgvaxpancreaswithcyclophosphamideandcrs207withorwithoutnivolumabinpatientswithpreviouslytreatedmetastaticpancreaticadenocarcinomastellar AT crocenzitodds randomizedphaseiistudyofthesafetyefficacyandimmuneresponseofgvaxpancreaswithcyclophosphamideandcrs207withorwithoutnivolumabinpatientswithpreviouslytreatedmetastaticpancreaticadenocarcinomastellar AT urumjennifern randomizedphaseiistudyofthesafetyefficacyandimmuneresponseofgvaxpancreaswithcyclophosphamideandcrs207withorwithoutnivolumabinpatientswithpreviouslytreatedmetastaticpancreaticadenocarcinomastellar AT lutzericr randomizedphaseiistudyofthesafetyefficacyandimmuneresponseofgvaxpancreaswithcyclophosphamideandcrs207withorwithoutnivolumabinpatientswithpreviouslytreatedmetastaticpancreaticadenocarcinomastellar AT laherudaniela randomizedphaseiistudyofthesafetyefficacyandimmuneresponseofgvaxpancreaswithcyclophosphamideandcrs207withorwithoutnivolumabinpatientswithpreviouslytreatedmetastaticpancreaticadenocarcinomastellar AT sugarelizabetha randomizedphaseiistudyofthesafetyefficacyandimmuneresponseofgvaxpancreaswithcyclophosphamideandcrs207withorwithoutnivolumabinpatientswithpreviouslytreatedmetastaticpancreaticadenocarcinomastellar AT vonderheideroberth randomizedphaseiistudyofthesafetyefficacyandimmuneresponseofgvaxpancreaswithcyclophosphamideandcrs207withorwithoutnivolumabinpatientswithpreviouslytreatedmetastaticpancreaticadenocarcinomastellar AT fishergeorgea randomizedphaseiistudyofthesafetyefficacyandimmuneresponseofgvaxpancreaswithcyclophosphamideandcrs207withorwithoutnivolumabinpatientswithpreviouslytreatedmetastaticpancreaticadenocarcinomastellar AT koandrewh randomizedphaseiistudyofthesafetyefficacyandimmuneresponseofgvaxpancreaswithcyclophosphamideandcrs207withorwithoutnivolumabinpatientswithpreviouslytreatedmetastaticpancreaticadenocarcinomastellar AT murphyaimeel randomizedphaseiistudyofthesafetyefficacyandimmuneresponseofgvaxpancreaswithcyclophosphamideandcrs207withorwithoutnivolumabinpatientswithpreviouslytreatedmetastaticpancreaticadenocarcinomastellar AT mcdougallkatherine randomizedphaseiistudyofthesafetyefficacyandimmuneresponseofgvaxpancreaswithcyclophosphamideandcrs207withorwithoutnivolumabinpatientswithpreviouslytreatedmetastaticpancreaticadenocarcinomastellar AT ferbersandy randomizedphaseiistudyofthesafetyefficacyandimmuneresponseofgvaxpancreaswithcyclophosphamideandcrs207withorwithoutnivolumabinpatientswithpreviouslytreatedmetastaticpancreaticadenocarcinomastellar AT brockstedtdirkg randomizedphaseiistudyofthesafetyefficacyandimmuneresponseofgvaxpancreaswithcyclophosphamideandcrs207withorwithoutnivolumabinpatientswithpreviouslytreatedmetastaticpancreaticadenocarcinomastellar AT jaffeeelizabethm randomizedphaseiistudyofthesafetyefficacyandimmuneresponseofgvaxpancreaswithcyclophosphamideandcrs207withorwithoutnivolumabinpatientswithpreviouslytreatedmetastaticpancreaticadenocarcinomastellar |